Overview

ACT-GLOBAL Adaptive Platform Trial for Stroke

Status:
RECRUITING
Trial end date:
2034-09-01
Target enrollment:
Participant gender:
Summary
Stroke is causing 6.6 million deaths and is a major cause of disability worldwide in 2019. There remains an urgent need for interventions that improve outcomes which can be implemented with wide applicability for stroke. ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage, randomised, global adaptive platform trial for stroke, aiming to identify the treatment/s associated with the highest chance of improving outcome in stroke patients. In ACT-GLOBAL multiple questions will be evaluated simultaneously and sequentially as data accrues and can evaluate interactions between different treatment options.
Phase:
PHASE3
Details
Lead Sponsor:
The George Institute
Collaborators:
Berry Consultants
University of Calgary
Treatments:
Colchicine